10/5/2026
Psyence BioMed to manufacture ibogaine in Texas with Benuvia
Psyence BioMed partners with Benuvia for U.S. ibogaine production, aiming to advance clinical research.
Topic archive
jody aufrichtig
8 stories
10/5/2026
Psyence BioMed partners with Benuvia for ibogaine production
Agreement aims to produce pharmaceutical-grade ibogaine in Texas facility.
9/28/2026
Psyence Biomedical secures $1.3M ibogaine licensing deal
Texas subsidiary gains exclusive U.S. rights to PsyLabs' ibogaine
9/23/2026
Psyence BioMed announces ibogaine investment and trial plans
Psyence BioMed to invest $5M in PsyLabs, plans Texas ibogaine trial.
9/14/2026
Psyence BioMed forms Texas entity for U.S. ibogaine research
Texas Ibogaine Research Corporation to spearhead U.S. ibogaine development efforts.
8/19/2026
Psyence BioMed supports U.S. push for ibogaine development
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Psyence BioMed backs Trump ibogaine initiative
Company aligns with U.S. efforts to advance ibogaine research.
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.